The stock price of Zomedica Corp (AMEX: ZOM) has surged by 1.21 when compared to previous closing price of 0.14, but the company has seen a 1.43% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-01 that Zomedica Corp. (ZOM) Q4 2023 Earnings Call Transcript
Is It Worth Investing in Zomedica Corp (AMEX: ZOM) Right Now?
The 36-month beta value for ZOM is also noteworthy at 0.99. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZOM is 964.36M, and at present, short sellers hold a 6.00% of that float. The average trading volume of ZOM on April 08, 2024 was 5.67M shares.
ZOM’s Market Performance
The stock of Zomedica Corp (ZOM) has seen a 1.43% increase in the past week, with a 2.90% rise in the past month, and a -20.58% fall in the past quarter. The volatility ratio for the week is 5.98%, and the volatility levels for the past 30 days are at 5.25% for ZOM. The simple moving average for the past 20 days is 3.43% for ZOM’s stock, with a -16.84% simple moving average for the past 200 days.
Analysts’ Opinion of ZOM
Many brokerage firms have already submitted their reports for ZOM stocks, with Dawson James repeating the rating for ZOM by listing it as a “Buy.” The predicted price for ZOM in the upcoming period, according to Dawson James is $6 based on the research report published on January 06, 2023 of the previous year 2023.
ZOM Trading at 5.78% from the 50-Day Moving Average
After a stumble in the market that brought ZOM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.04% of loss for the given period.
Volatility was left at 5.25%, however, over the last 30 days, the volatility rate increased by 5.98%, as shares surge +0.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.82% upper at present.
During the last 5 trading sessions, ZOM rose by +0.71%, which changed the moving average for the period of 200-days by -33.14% in comparison to the 20-day moving average, which settled at $0.1373. In addition, Zomedica Corp saw -29.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZOM starting from POWERS JOHNNY D, who purchase 100,000 shares at the price of $0.17 back on Dec 15 ’23. After this action, POWERS JOHNNY D now owns 1,950 shares of Zomedica Corp, valued at $16,500 using the latest closing price.
POWERS JOHNNY D, the Director of Zomedica Corp, purchase 100,000 shares at $0.17 during a trade that took place back on Nov 17 ’23, which means that POWERS JOHNNY D is holding 1,850,000 shares at $16,600 based on the most recent closing price.
Stock Fundamentals for ZOM
Current profitability levels for the company are sitting at:
- -1.25 for the present operating margin
- 0.61 for the gross margin
The net margin for Zomedica Corp stands at -1.37. The total capital return value is set at -0.13. Equity return is now at value -13.61, with -12.96 for asset returns.
Based on Zomedica Corp (ZOM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -5.78. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -658.15.
Currently, EBITDA for the company is -25.29 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 5.13. The receivables turnover for the company is 11.46for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.06.
Conclusion
In summary, Zomedica Corp (ZOM) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
